William McCall, MD
Psychiatry · Augusta, GANPI 1902881485
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $41,634 of the $62,785 with a category attached, or 66.3%. 14 manufacturers reported payments, led by Idorsia Pharmaceuticals US Inc at 47.7% of the total. Reporting peaked in 2023 at $26,672 and has fallen 86.0% since, to $3,731 in 2025. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 102 payments — averaging $615.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Idorsia Pharmaceuticals US Inc$30K
- Johnson & Johnson$11K
- Livanova USA, Inc.$6K
- Jazz Pharmaceuticals Inc.$5K
- Genentech, Inc.$4K
- Eisai Inc.$4K
- plus $2K from 8 others
Across 3 payments — averaging $6460.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Idorsia Pharmaceuticals US Inc$10K
- Janssen Research & Development, LLC$9K
What the payments were for
- Consulting fees$41,63466%
- Speaking & faculty fees$9,54015%
- Travel & lodging$9,17515%
- Food & beverage$2,0953%
- Education$3411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Idorsia Pharmaceuticals US Inc | 39 | $29,957 |
| Johnson & Johnson | 20 | $11,136 |
| Livanova USA, Inc. | 7 | $6,276 |
| Jazz Pharmaceuticals Inc. | 14 | $5,321 |
| Genentech, Inc. | 2 | $4,230 |
| Eisai Inc. | 2 | $3,636 |
| Sunovion Pharmaceuticals Inc. | 1 | $1,640 |
| Harmony Biosciences LLC | 3 | $253 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $122 |
| Sage Therapeutics, LLC | 1 | $50 |
| Otsuka America Pharmaceutical, Inc. | 1 | $50 |
| Alkermes, Inc. | 2 | $42 |
| Lundbeck LLC | 2 | $40 |
| CSL Behring | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$62,785 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lorazepam | 19 | $34 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Augusta
- Marshall BedderAugusta$182K
- Joseph McEvoyAugusta$36K
- Mary TysonAugusta$17K
- Prakash MeraiAugusta$13K
- Richard PettyLoganville$2.9M
- Ann GrooverCalhoun$1.4M
- Todd AntinDecatur$1M
- Michael BanovMarietta$733K
- Ben HunterBrookhaven$499K
- Joel MorganValdosta$337K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.